Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Febrile Neutropenia
Conditions
Febrile Neutropenia
Trial Timeline
Mar 1, 2007 → May 1, 2008
NCT ID
NCT00421187About Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) is a approved stage product being developed by Gilead Sciences for Febrile Neutropenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00421187. Target conditions include Febrile Neutropenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00421187 | Approved | Terminated |
Competing Products
8 competing products in Febrile Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |